Next-Generation Cancer Immunotherapy Using Quantum Computing Selected for NEDO Demonstration Program -A Joint R&D Project by NEC, Taiho Pharmaceutical, the Japanese Foundation for Cancer Research, AIST, and Waseda University
Global Site
Breadcrumb navigation
NEC's AI Drug Development Business
We are challenging various activities related to drug development, such as personalized cancer immunotherapy using broader IT technologies including AI.
Latest News
Press Release
Oct 2, 2026
Press Release
Sep 3, 2026
Press Release
Apr 3, 2026
Press Release
Dec 10, 2025
Press Release
Nov 28, 2025
Our Challenge for the best cancer immunotherapy
We develop the personalized Neoantigen vaccine utilizing our cutting-edge AI.
World top class Neoantigens prediction
We are developing a personalized cancer immunotherapy pipeline using the NEC Immune Profiler, which combines the technologies of both NEC and NEC OncoImmunity.
NEC Immune Profiler
NEC OncoImmunity AS offers software solutions powered by a prediction engine using artificial intelligence known as the NEC Immune Profiler, that predicts from next generation sequencing data true neoantigens for personalized cancer immunotherapy and cancer immunotherapy biomarkers.
Collaboration partner
Target Indication： Ovarian cancer, Head and neck cancer
Transgene and NEC are collaboratively working on developing the personalized cancer immunotherapy, TG4050, with combination Transgene’s myvac® and NEC’s Neoantigen prediction system. Two clinical trials is underway.
NEC has made a Series A strategic investment in BostonGene, a pioneer in the use of biomedical software for advanced patient analysis. BostonGene has discovered, developed, and patented a holistic approach to cancer treatment by defining the optimal therapy combination for individual patients, with a particular focus on immuno and targeted therapies.
Target Indication： Betacoronavirus
NEC and CEPI are working to advance the development of vaccines that provide broad protection against SARS-CoV-2 and other betacoronaviruses.
Consortium
CONNECT is a landmark public-private initiative, the Norwegian Precision Cancer Medicine Implementation Consortium. The aim is to ensure infrastructure and collaboration on diagnostics, clinical trials, implementation of advanced precision medicine and use of health data, e.g., for health economics analysis. By joining the network of this consortium and leveraging advanced real-world data, NEC hopes to reinforce and accelerate its personalized cancer immunotherapy activities.
